FDA issues genome‑editing draft
The FDA released draft guidance on genome‑editing safety, setting out updated expectations for documentation and risk assessment around edited biological material. The draft guidance was reported as part of a broader FDA policy roundup and is positioned as a regulatory clarification rather than a rollback of oversight. (cen.acs.org)
Genome editing works like a search-and-replace tool for DNA, and the Food and Drug Administration on April 14 released draft instructions for checking whether those edits hit the wrong spots. (fda.gov) The draft guidance is titled *Safety Assessment of Genome Editing in Human Gene Therapy Products Using Next-Generation Sequencing* and applies to sponsors developing human gene therapy products that use genome editing. The agency said the recommendations are meant for nonclinical studies submitted with investigational new drug applications and Biologics License Applications. (fda.gov) Next-generation sequencing is a high-throughput DNA reading method, and the draft tells companies to use it with bioinformatics software to look for off-target edits and for “loss of genome integrity,” meaning larger unintended changes such as deletions, rearrangements, or inserted DNA. FDA said those risks can arise when gene-editing tools cut DNA and the cell repairs the break imperfectly. (fda.gov) The agency said the document builds on its January 2024 final guidance, *Human Gene Therapy Products Incorporating Human Genome Editing*, which covered broader development issues for gene-edited therapies. The new draft narrows in on one part of that process: how sponsors should generate and present sequencing-based safety data before human studies expand or products move toward approval. (fda.gov) FDA published the notice in the *Federal Register* on April 15 and set July 14, 2026, as the deadline for public comments. The docket number is FDA-2026-D-1255. (govinfo.gov) The document does not create a new approval pathway or remove existing review requirements. FDA described it as a draft guidance for industry, meaning it lays out the agency’s current thinking and can change after comments are reviewed. (fda.gov) Regulators and developers have spent the past several years trying to separate intended edits from accidental ones as CRISPR-based and other genome-editing therapies move from lab work into clinical development. FDA said standardized sequencing methods could help sponsors produce more consistent safety packages across programs. (fda.gov) Trade and policy coverage this week described the move as a clarification of what FDA wants to see in safety testing, not a pullback in oversight. That framing matches the agency’s own description of the draft as an add-on to its 2024 genome-editing guidance rather than a replacement for it. (cen.acs.org)
